SI1181294T1 - Novel derivatives and analogues of galanthamin - Google Patents

Novel derivatives and analogues of galanthamin

Info

Publication number
SI1181294T1
SI1181294T1 SI200130081T SI200130081T SI1181294T1 SI 1181294 T1 SI1181294 T1 SI 1181294T1 SI 200130081 T SI200130081 T SI 200130081T SI 200130081 T SI200130081 T SI 200130081T SI 1181294 T1 SI1181294 T1 SI 1181294T1
Authority
SI
Slovenia
Prior art keywords
galanthamin
analogues
novel derivatives
derivatives
novel
Prior art date
Application number
SI200130081T
Other languages
English (en)
Slovenian (sl)
Inventor
Ulrich Jordis
Johannes FR�HLICH
Matthias Treu
Manfred Hirnschall
Laszlo Czollner
Beate K�LZ
Stefan Welzig
Original Assignee
Sanochemia Pharmazeutica Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutica Aktiengesellschaft filed Critical Sanochemia Pharmazeutica Aktiengesellschaft
Publication of SI1181294T1 publication Critical patent/SI1181294T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SI200130081T 2000-03-31 2001-03-22 Novel derivatives and analogues of galanthamin SI1181294T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT5462000 2000-03-31
AT2382001 2001-02-15
PCT/AT2001/000082 WO2001074820A1 (fr) 2000-03-31 2001-03-22 Nouveaux derives et analogues de la galanthamine

Publications (1)

Publication Number Publication Date
SI1181294T1 true SI1181294T1 (en) 2004-08-31

Family

ID=25608130

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130081T SI1181294T1 (en) 2000-03-31 2001-03-22 Novel derivatives and analogues of galanthamin

Country Status (26)

Country Link
US (2) US7166588B2 (fr)
EP (1) EP1181294B1 (fr)
JP (1) JP2003529602A (fr)
CN (1) CN1380883A (fr)
AT (1) ATE263171T1 (fr)
AU (1) AU785385B2 (fr)
BG (1) BG65134B1 (fr)
BR (1) BR0105563A (fr)
CA (1) CA2368966A1 (fr)
CZ (1) CZ300160B6 (fr)
DE (1) DE50101827D1 (fr)
DK (1) DK1181294T3 (fr)
ES (1) ES2215885T3 (fr)
HK (2) HK1045990A1 (fr)
HU (1) HUP0202233A3 (fr)
IS (1) IS2287B (fr)
MX (1) MXPA01012275A (fr)
NO (1) NO326458B1 (fr)
NZ (1) NZ516302A (fr)
PL (1) PL202463B1 (fr)
PT (1) PT1181294E (fr)
RU (1) RU2241001C2 (fr)
SI (1) SI1181294T1 (fr)
SK (1) SK285909B6 (fr)
TR (1) TR200400857T4 (fr)
WO (1) WO2001074820A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
EP1681291A1 (fr) * 2002-03-25 2006-07-19 Sanochemia Pharmazeutika Aktiengesellschaft Procédé de préparation de la norgalanthamine, de ses isomères, sels et hydrates
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
US7877350B2 (en) * 2005-06-27 2011-01-25 Ab Initio Technology Llc Managing metadata for graph-based computations
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009508903A (ja) * 2005-09-22 2009-03-05 ガラントス ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング 認知障害を伴う疾患の治療に用いるための脳血液関門透過性が改善されたコリン作用増強剤
WO2008022365A2 (fr) * 2006-08-24 2008-02-28 Sanochemia Ltd. Agent servant à influencer les effets de composés organophosphorés et utilisation de galanthamine, de ses dérivés et analogues pour la fabrication d'un tel agent
ES2463715T3 (es) 2008-04-14 2014-05-29 Neurodyn Life Sciences Inc. Derivados de galantamina como profármacos para el tratamiento de enfermedades del cerebro humano
BG110141A (en) * 2008-05-23 2009-12-31 "Софарма" Ад GALANTAMINE DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE
EP2583168B1 (fr) 2010-06-15 2017-11-08 Ab Initio Technology LLC Chargement dynamique de calculs basés sur des graphes
WO2013160728A1 (fr) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Composés à double ciblage pour le traitement de la maladie d'alzheimer
US10108521B2 (en) * 2012-11-16 2018-10-23 Ab Initio Technology Llc Dynamic component performance monitoring
WO2015085152A1 (fr) 2013-12-05 2015-06-11 Ab Initio Technology Llc Gestion d'interfaces pour des graphes de flux de données composés de sous-graphes
CA2959389A1 (fr) 2014-09-02 2016-03-10 Ab Initio Technology Llc Compilation de specifications de programme basees sur des graphiques avec groupage automatise de composantes graphiques sur la base de l'identification de connexions de port de donnees particulieres
CN107145344B (zh) 2014-09-02 2020-12-04 起元科技有限公司 在基于图的程序中指定组件
US10657134B2 (en) 2015-08-05 2020-05-19 Ab Initio Technology Llc Selecting queries for execution on a stream of real-time data
US12006301B1 (en) 2021-05-13 2024-06-11 Florida A&M University And synthesis of dual 5-HT1A and 5-HT7 receptor ligands

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
AU632458B2 (en) * 1987-05-04 1993-01-07 Bonnie Davis Compounds for the treatment of alzheimer's disease
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
KR100352212B1 (ko) * 1994-10-21 2003-04-18 자노케미아 파마조이티카 악티엔게젤샤프트 4a,5,9,10,11,12-헥사히드로-6H-벤조푸로[3a,3,2-ef][2]벤즈아제핀유도체의제조방법
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
GB9716879D0 (en) * 1997-08-08 1997-10-15 Shire Int Licensing Bv Treatment of attention deficit disorders
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
HK1045990A1 (en) 2002-12-20
BR0105563A (pt) 2002-04-02
EP1181294A1 (fr) 2002-02-27
NZ516302A (en) 2004-02-27
TR200400857T4 (tr) 2004-06-21
JP2003529602A (ja) 2003-10-07
ES2215885T3 (es) 2004-10-16
PT1181294E (pt) 2004-07-30
DK1181294T3 (da) 2004-08-02
SK17022001A3 (sk) 2003-02-04
IS6174A (is) 2001-11-23
AU785385B2 (en) 2007-03-29
NO326458B1 (no) 2008-12-08
MXPA01012275A (es) 2003-06-24
HUP0202233A2 (hu) 2002-11-28
EP1181294B1 (fr) 2004-03-31
BG65134B1 (bg) 2007-03-30
US20070027138A1 (en) 2007-02-01
PL202463B1 (pl) 2009-06-30
WO2001074820A1 (fr) 2001-10-11
AU4208501A (en) 2001-10-15
US7166588B2 (en) 2007-01-23
CZ300160B6 (cs) 2009-02-25
RU2241001C2 (ru) 2004-11-27
CN1380883A (zh) 2002-11-20
IS2287B (is) 2007-10-15
HUP0202233A3 (en) 2004-12-28
BG106155A (en) 2002-08-30
HK1049832A1 (zh) 2003-05-30
SK285909B6 (sk) 2007-10-04
PL352638A1 (en) 2003-09-08
CZ20014178A3 (cs) 2002-11-13
US20030199493A1 (en) 2003-10-23
NO20015857D0 (no) 2001-11-30
CA2368966A1 (fr) 2001-10-11
NO20015857L (no) 2002-01-29
ATE263171T1 (de) 2004-04-15
DE50101827D1 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
SE0000540D0 (sv) New compounds
SI1181294T1 (en) Novel derivatives and analogues of galanthamin
CY1107634T1 (el) Φαρμακευτικη συνθεση
BE2017C018I2 (fr)
JO2654B1 (en) Multiple aryl caroxa amides are useful as lipid - lowering agents
TW200510368A (en) Pharmaceutical compositions and combinations of novel non-imidazole compounds
DOP2001000151A (es) Derivados de imidazopirimidina y derivados de triazolopimidina.
YU83602A (sh) Derivati fenilglicina
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
GB9919776D0 (en) Compoujnds
DE60135919D1 (de) Farnesyl transferase-hemmende 6-heterocyclylmethyl-chinolin und chinazol-derivate
AU2002224885A1 (en) Morpholine derivatives as antagonists of orexin receptors
HK1069395A1 (en) Phthalazinone derivatives 2,3
BG106585A (en) Kinase inhibitors as therapeutic agents
MXPA02012033A (es) Derivados de 2-aminocarbonil-9h-purina.
HK1053309A1 (en) Method for synthesis of perindopril and its pharmaceutically acceptable salts
PL342113A1 (en) Sulphonamidic derivatives useful as precursors of aspartil protease inhibitors
GB0127903D0 (en) Improvements relating to organic compounds
DE60121461D1 (de) Kondensierte pyridoindolderivate
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
MXPA02012054A (es) Compuestos de dicetopiracina tetraciclica como inhibidores de la fosfodiesterasa v.
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
PL365909A1 (en) Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
MXPA03003942A (es) Compuestos bis-heterociclicos con actividad antitumoral y quimiosensibilizante.
MXPA02007173A (es) Compuestos calciliticos.